Vaccination of immunocompetent elderly subjects with a live attenuated Oka strain of varicella zoster virus: a randomized, controlled, dose-response trial
- PMID: 10689152
- DOI: 10.1016/s0264-410x(99)00510-1
Vaccination of immunocompetent elderly subjects with a live attenuated Oka strain of varicella zoster virus: a randomized, controlled, dose-response trial
Abstract
After primary infection in childhood, varicella zoster virus (VZV) remains latent in the dorsal route ganglia. Its reactivation later in life can lead to a zoster episode. VZV-specific, T-cell-mediated immunity (VZV-CMI) is likely to be important in preventing symptomatic reactivation. As CMI declines with age, a vaccine enhancing VZV-CMI might be effective in decreasing the incidence or severity of zoster in elderly subjects. A randomized, double blind controlled trial assessing CMI responses of elderly subjects immunized with a live attenuated, VZV-Oka vaccine was conducted. Two hundred healthy volunteers (55-75 years of age) received either a single injection of the VZV vaccine (PMC), containing 3200 (Oka 3200), 8500 (Oka 8500), or 41,650 (Oka 41650) PFU of live VZV, or a pneumococcus vaccine control group (Pneumo 23((R)). The immune response to VZV was assessed by measuring the T-cell response to VZV antigens, i.e. proliferation (stimulation index, SI), precursor cell frequency (PCF), cytokine secretion, and antibody titers. Six weeks post-vaccination, VZV-specific SI (adjusted mean values) was significantly greater (P<0.0001) in the 3 vaccine groups (with SI=5. 6 for Oka 3200; SI=5.0 for Oka 8500, and SI=7.2 for Oka 41,650) than in the control group (SI=2.9). The increase in PCF was striking, with 72.4, 91.2 and 85.1 precursors per million cells respectively in these 3 vaccine groups, vs 26.3 in the control group. No significant IL-4 secretion was observed in any subject, whereas the presence of IFN-gamma secretion was found to correlate with good responder status. The increase of these CMI parameters did not depend upon the titer of virus injected. Geometric mean titers of VZV antibodies increased in all vaccine groups and remained unchanged in the control group. Nevertheless, no correlation between the antibody response and the cell-mediated response was found. Live attenuated VZV vaccine caused a significant increase in VZV-CMI in a healthy, elderly population. No relationship between vaccine dose and the intensity of the specific response was found.
Similar articles
-
A dose-response study of a live attenuated varicella-zoster virus (Oka strain) vaccine administered to adults 55 years of age and older.J Infect Dis. 1998 Nov;178 Suppl 1:S99-103. doi: 10.1086/514265. J Infect Dis. 1998. PMID: 9852985 Clinical Trial.
-
Varicella-zoster virus-specific immune responses in elderly recipients of a herpes zoster vaccine.J Infect Dis. 2008 Mar 15;197(6):825-35. doi: 10.1086/528696. J Infect Dis. 2008. PMID: 18419349 Free PMC article. Clinical Trial.
-
Immune response of elderly individuals to a live attenuated varicella vaccine.J Infect Dis. 1992 Aug;166(2):253-9. doi: 10.1093/infdis/166.2.253. J Infect Dis. 1992. PMID: 1321859 Clinical Trial.
-
Zoster vaccine: current status and future prospects.Clin Infect Dis. 2010 Jul 15;51(2):197-213. doi: 10.1086/653605. Clin Infect Dis. 2010. PMID: 20550454 Review.
-
Immunization of the elderly to boost immunity against varicella-zoster virus (VZV) as assessed by VZV skin test reaction.Arch Virol Suppl. 2001;(17):161-72. doi: 10.1007/978-3-7091-6259-0_17. Arch Virol Suppl. 2001. PMID: 11339545 Review.
Cited by
-
Immunogenicity and safety of ZOSTAVAX(®) approaching expiry potency in individuals aged ≥50 years.Hum Vaccin. 2011 Oct;7(10):1060-5. doi: 10.4161/hv.7.10.16480. Epub 2011 Oct 1. Hum Vaccin. 2011. PMID: 21941091 Free PMC article. Clinical Trial.
-
Prophylaxis of herpesvirus infections in immunocompetent and immunocompromised older patients.Drugs Aging. 2002;19(5):343-54. doi: 10.2165/00002512-200219050-00003. Drugs Aging. 2002. PMID: 12093321 Review.
-
Varicella zoster virus. Recent advances in management.Can Fam Physician. 2001 Nov;47:2299-304. Can Fam Physician. 2001. PMID: 11768928 Free PMC article. Review.
-
Prevalence and healthcare utilization of herpes zoster and postherpetic neuralgia in South Korea: disparity among patients with different immune statuses.Epidemiol Health. 2014 Aug 14;36:e2014012. doi: 10.4178/epih/e2014012. eCollection 2014. Epidemiol Health. 2014. PMID: 25119454 Free PMC article.
-
Reducing the burden of Herpes Zoster in Italy.Hum Vaccin Immunother. 2015;11(1):101-7. doi: 10.4161/hv.34363. Epub 2014 Nov 1. Hum Vaccin Immunother. 2015. PMID: 25483522 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials